Oslo, Norway, 14 February 2022

Nordic Nanovector ASA (the "Company") announces that an extraordinary general
meeting ("EGM") in the Company was held today at the Company's offices in
Kjelsåsveien 168B, 0884 Oslo. The EGM approved all items on the agenda,
including the authorisation to the board of directors ("Board") to increase the
share capital in connection with a potential repair offering as announced on 19
and 24 January 2022. The minutes from the EGM are attached and are also
available at www.nordicnanovector.com.

As previously announced, a repair offering is subject to (i) the prevailing
market price of the Company's shares, (ii) relevant corporate resolutions being
passed by the Company, including the approval by the Board, and (iii) the
approval of a prospectus by the Norwegian Financial Supervisory Authority. The
Company expects to announce an update as to the implementation of a repair
offering next week.

For further information, please contact:

IR enquiries Malene Brondberg, CFO

Cell: +44 7561 431 762

Email: ir@nordicnanovector.com

Media Enquiries

Mark Swallow/Frazer Hall/David Dible (MEDiSTRAVA Consulting)
Tel: +44 203 926 8535
Email:
nordicnanovector@ (nordicnanovector@citigatedewerogerson.com)medistrava (nordicn
a
novector@citigatedewerogerson.com).com (nordicnanovector@citigatedewerogerson.co
m
)

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs. The Company aspires to become a
leader in the development of CD37-targeted therapies for haematological cancers
and immune diseases. Nordic Nanovector's lead clinical-stage candidate is
Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with
substantial unmet medical need, representing a growing market forecast to be
worth nearly USD 29 billion by 2026. Nordic Nanovector retains global marketing
rights to Betalutin® and intends to actively participate in the
commercialisation of Betalutin® in the US and other major markets.

Further information can be found
at www.nordicnanovector.com (https://nam10.safelinks.protection.outlook.com/?url
=
http%3A%2F%2Fwww.nordicnanovector.com%2F&data=04%7C01%7CMark.Swallow%40medistrav
a
.com%7C278fdef034c24fd8526f08d9a2dc443d%7C5c24475f929349d0b4e1ba6d190e92f9%7C0%7
C
0%7C637719889230015300%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luM
z
IiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=UWkw4lhdkxg1eVMeCWpeWy6v9jzAw%2FB3
m
buhdiRgU%2F0%3D&reserved=0).

This information is subject to a duty of disclosure pursuant to Section 5-12 of
the Securities Trading Act.